Pyrukynd

bullseye darts target

Pharma

Agios' Pyrukynd misses the mark in first pediatric study

The trial in PK deficient children who receive regular transfusions didn't meet its primary endpoint.

Zoey Becker Aug 1, 2024 1:08pm

Thalassemia

Agios charts broad path for oral thalassemia med after trial win

Jan 3, 2024 10:49am

Dementia

Agios' first-in-class PK activator Pyrukynd scores FDA nod

Feb 17, 2022 4:50pm